Lorenzo Piemonti, Giovanni Landoni, Antonio Voza, Massimo Puoti, Ivan Gentile, Nicola Coppola, Stefano Nava, Alessia Mattei, Franco Marinangeli, Giulia Marchetti, Paolo Bonfanti, Claudio Maria Mastroianni, Matteo Bassetti, Ernesto Crisafulli, Paolo Antonio Grossi, Alberto Zangrillo, Antonio Desai, Marco Merli, Maria Foggia, Marco Carpano, Lorenzo Schiavoni, Antonella D'Arminio Monforte, Luca Bisi, Gianluca Russo, Fabiana Busti, Cristina Rovelli, Elisabetta Perrotta, Giovanni Goisis, Elizabeth M Gavioli, Sophie Toya, Maria De Pizzol, Flavio Mantelli, Marcello Allegretti, Enrico Maria Minnella
INTRODUCTION: Polymorphonuclear cell influx into the interstitial and bronchoalveolar spaces is a cardinal feature of severe coronavirus disease 2019 (COVID-19), principally mediated by interleukin-8 (IL-8). We sought to determine whether reparixin, a novel IL-8 pathway inhibitor, could reduce disease progression in patients hospitalized with severe COVID-19 pneumonia. METHODS: In this Phase 3, randomized, double-blind, placebo-controlled, multicenter study, hospitalized adult patients with severe COVID-19 pneumonia were randomized 2:1 to receive oral reparixin 1200 mg three times daily or placebo for up to 21 days or until hospital discharge...
October 5, 2023: Infectious Diseases and Therapy